Urolithin A mitigates behavioural and synaptic deficits associated with epilepsy

Authors: Mishra, Shefali; Verma, Vijaya; Pradhan, Sambit; Dwivedi, Manish Kumar; Jorwal, Pooja; Sikdar, Sujit Kumar; Kumar, Vimlesh; Thilagar, P; Clement, James P; Nongthomba, Upendra

Source journal: BMC neuroscience (2026-08-21)

DOI: 10.1186/s12868-026-01036-z

Abstract

BACKGROUND: The persistence of drug-resistant epilepsy highlights the need for new therapies that target novel mechanisms while maintaining synaptic strength and minimizing side effects. Small molecules of natural origin with anti-epileptogenic potential can influence altered synaptic deficits and reducing seizure threshold, offering a strategy to restore cellular energy homeostasis and slow the progression of epilepsy and associated comorbidities. METHODS: We used a combination of approaches including behavioural assays, immunostaining and electrophysiological recordings to study the synaptic contributions to reduced seizure-threshold in both Drosophila and mouse models of epilepsy. In addition, we used affinity-purification with synthesized beads specific for our small molecule to identify its cellular partners. RESULTS: We found that administration of Urolithin-A (UA), a small molecule of natural origin, mitigated behavioural and synaptic dysfunctions under chemically and genetically induced epileptic conditions in Drosophila. Additionally, chronic treatment with UA attenuated the altered single-cell and network synaptic transmission in PTZ-induced chronic kindling of mice. However, UA exerted no seizure-suppressive effects in in vitro epileptic conditions, suggesting the absence of acute anti-epileptic effects. In addition, we identified the direct interactor of UA as the complex of tubulin dimer and VDAC1. Molecular docking analyses also predicted that urolithin A interacts with VDAC1. Consistent with the neuroprotective role of VDAC1 downregulation reported in previous studies, neuron-specific knockdown of VDAC1 in Drosophila phenocopied the effects of UA. CONCLUSIONS: Collectively, our data show that UA exerts disease-modifying anti-epileptic effects in both Drosophila and mouse models with VDAC1 identified as a critical functional mediator; however, direct functional modulation of VDAC1 and associated partners by UA will require further experimental validation. These findings provide the blueprint for future drug discovery targeting VDAC1-dependent pathways.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.